Prices delayed by at least 15 minutes | Print
Kala BIO (KALA)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
Address
490 Arsenal Way
Suite 120
Watertown
MA
USA
02472
Telephone
+1 781 9965252
Forecast key dates
| Name | Key Date |
|---|---|
| Kala Bio Inc Fourth Quarter Earnings Results for 2024 | 2025-03-28T00:00:00 |
| Kala Bio Inc Annual Report for 2024 | 2025-03-28T00:00:00 |
| Kala Bio Inc Third Quarter Earnings Results for 2024 | 2024-11-13T00:00:00 |
| Kala Bio Inc Second Quarter Earnings Results for 2024 | 2024-08-02T00:00:00 |
| Kala Pharmaceuticals Inc Annual General Meeting for 2024 | 2024-06-21T11:00:00 |
| Kala Pharmaceuticals Inc First Quarter Earnings Results for 2024 | 2024-05-09T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Kala Bio Inc Fourth Quarter Earnings Results for 2023 | 2024-03-29T00:00:00 |
| Kala Bio Inc Annual Report for 2023 | 2024-03-29T00:00:00 |
| KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference | 2024-03-04T12:50:00 |
| KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference | 2024-02-13T12:00:00 |
| Kala Bio Inc Third Quarter Earnings Results for 2023 | 2023-11-13T00:00:00 |
| Kala Bio Inc Second Quarter Earnings Results for 2023 | 2023-08-04T00:00:00 |
| Kala Pharmaceuticals Inc Annual General Meeting for 2023 | 2023-06-22T11:00:00 |
| Kala Pharmaceuticals Inc First Quarter Earnings Results for 2023 | 2023-05-09T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.